Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Everolimus

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    RAD

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 252,793Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA accepts NDA for Roche’s giredestrant in ESR1-Mutated
    FDA accepts NDA for Roche’s giredestrant in ESR1-Mutated

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/20/3241682/0/en/FDA-accepts-New-Drug-Application-for-Roche-s-giredestrant-in-ESR1-mutated-ER-positive-advanced-breast-cancer.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Biocon Arm Gets USFDA Nod For Generic Everolimus Tablets
    Biocon Arm Gets USFDA Nod For Generic Everolimus Tablets

    12 Jan 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-arm-gets-usfda-nod-for-generic-everolimus-tablets/articleshow/126479442.cms

    ECONOMICTIMES
    12 Jan 2026
    Share Share
    Biocon Pharma’s Generics Everolimus Receives Approval in US
    Biocon Pharma’s Generics Everolimus Receives Approval in US

    09 Jan 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217216

    FDA
    09 Jan 2026
    Share Share
    Oncotelic, Sapu Nano Unveil Deciparticle-Led Cancer Biomarker
    Oncotelic, Sapu Nano Unveil Deciparticle-Led Cancer Biomarker

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199970/0/en/Oncotelic-and-Sapu-Nano-Announce-DeciparticleTM-Led-Biomarker-Framework-Identifying-Tumors-Most-Likely-to-Respond-to-IV-Sapu003-an-Intravenous-Everolimus-Nanomedicine.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Sapu Nano Reveals IV Sapu003 Reduces Everolimus GI Accumulation
    Sapu Nano Reveals IV Sapu003 Reduces Everolimus GI Accumulation

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199513/0/en/Sapu-Nano-Announces-New-PK-Data-Demonstrating-IV-Sapu003-Reduces-GI-Accumulation-of-Everolimus-up-to-67-Fold-Compared-With-Oral-Dosing.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    IV Sapu003 Shows 67x Lower GI Exposure vs Oral Everolimus
    IV Sapu003 Shows 67x Lower GI Exposure vs Oral Everolimus

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198954/0/en/Oncotelic-and-Sapu-Nano-Announces-New-PK-Data-Demonstrating-IV-Sapu003-Reduces-GI-Accumulation-of-Everolimus-up-to-67-Fold-Compared-With-Oral-Dosing.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.